SignalTrace

Toddler Eczema — Home Remedies vs Prescribed Care

John Montgomery30 min read

Toddler Eczema — Vault Index

Research Goal

Goal: Understand eczema (atopic dermatitis) in toddlers aged 1–4: what it is, its root causes and triggers, and how it is treated. Compare home/herbal remedies (Track A) with doctor-prescribed care (Track B) on evidence strength, safety, real-world parent experience, and outcomes.

Verdict

For a toddler with eczema, daily plain emollient plus correctly dosed topical steroid for flares, stepped up or down with a written plan, beats any home remedy. The home measures worth keeping are the ones that are really emollients (colloidal oatmeal, plain sunflower oil, petrolatum), and several “natural” remedies cause harm (olive and nut oils, essential oils, Compositae herbs, steroid-spiked “herbal” creams, unsupervised elimination diets). The biggest open question is whether good control in the toddler years changes the long-term course; no trial has shown it does. → Conclusion · Treatment Outcomes Comparison · Herbal and Home Remedies for Eczema · Parent Experiences

Not medical advice

Research for understanding only — not a substitute for diagnosis or a treatment plan from a clinician who has examined the child.

Unresolved

  • Unverified claims register: audit
  • Source conflicts are logged per topic in open_questions/*-conflicts.md (full list under Open Questions below)
  • Main open question: does early, good control change prognosis or the atopic march? → Eczema Prognosis, Atopic March

Seed entities (round 1)

  • Eczema Herpeticum — Widespread herpes simplex (HSV-1) infection of eczema; an emergency needing same-day aciclovir and specialist or hospital care.
  • Infected Eczema — Eczema with secondary bacterial (mostly S. aureus) or herpes infection: weeping, crusts, pus, fever. Urgent GP; blisters+fever = emergency.
  • Hard Water — High-calcium domestic water; linked to childhood eczema in observational studies, but the SWET trial found water softeners don’t treat it.
  • Staphylococcus aureus — Bacterium colonising ~70% of eczema lesions; causes impetiginised flares. Antibiotics only if a child is unwell or infection is spreading.
  • MHRA — UK regulator of medicines and devices; warned on aqueous cream, emollient fire risk and steroid-spiked ‘herbal’ eczema creams.
  • Adulterated Herbal Creams — ‘Natural’/herbal eczema creams repeatedly found by labs and the MHRA to hide potent steroids such as clobetasol or dexamethasone.
  • Bathing Frequency — Daily vs twice-weekly bathing in childhood eczema; small RCTs disagree, but soak-then-moisturise bathing is safe and may help acute flares.
  • Bleach Baths — Dilute hypochlorite baths for moderate-severe eczema; 2017 meta-analysis: no better than water; 2022 GRADE review: modest gain.
  • Wet Wrap Therapy — Damp cotton layer plus dry layer over emollient or steroid for severe flares; helps in practice but low-quality evidence it beats TCS alone.

Organisations (researched — round 5)

  • British Association of Dermatologists — UK dermatologists’ professional body and charity; publishes the atopic eczema patient leaflet and the 2024 joint TSW statement.
  • National Eczema Association — US eczema patient charity; runs the Seal of Acceptance, backs bleach baths, flags TSW as under-recognised, open to complementary care.
  • NICE — England’s health guidance body; publishes CG57 (eczema under 12s), QS44, NG190 and the CKS eczema summary.

Organisations (researched — round 12)

  • Cochrane — Systematic-review network; its Skin group’s eczema reviews (emollients, TCS, supplements, probiotics) anchor most Track A vs B verdicts.
  • European Medicines Agency — EU medicines regulator; via CHMP/PDCO sets EU paediatric eczema licences, often narrower than FDA’s (dupilumab, ruxolitinib, crisaborole).
  • FDA — US regulator: OTC monographs (hydrocortisone, oatmeal), 2006 TCI boxed warning; licensed dupilumab, crisaborole, ruxolitinib for young kids.
  • National Eczema Society — UK eczema charity (1975); nurse-supported helpline, factsheets used across this vault, co-author of the 2024 UK joint statement on TSW.

Organisations (researched — round 15)

  • American Academy of Dermatology — US dermatology body; first child-specific AD guidelines published April 2026 replace its 2014 guidance for under-18s.
  • HOME Initiative — International group setting the core outcome set for eczema trials: EASI (signs), POEM (symptoms), IDQoL/CDLQI (QoL), RECAP/ADCT (control).
  • SAHPRA — South Africa’s health-products regulator (ex-MCC): registers TCIs and dupilumab (AD from 6 y); phasing in complementary-medicine control.

Organisations (stubs — rounds 6–7)

  • National Fire Chiefs Council — UK fire and rescue leadership body; co-ran the 2020 MHRA emollient fire-risk campaign and publishes ‘Know the Fire Risk’ advice. (stub)
  • NHS England — Body overseeing the NHS in England; its low-value prescribing list removed routine bath and shower emollient prescriptions in 2019. (stub)
  • World Allergy Organization — International allergy federation; its 2015 GLAD-P guideline conditionally suggests probiotics to prevent eczema in high-risk families. (stub)

Organisations (stubs — round 9)

  • Allergy Society of South Africa — South African professional allergy society; members co-authored local eczema and food-allergy guidance. (stub)
  • Dermatological Society of South Africa — South African dermatologists’ society; its 2008 working group wrote the first SA atopic dermatitis guideline. (stub)
  • PrescQIPP — NHS-funded not-for-profit issuing cost-effective prescribing bulletins, incl. emollients and topical steroids for eczema. (stub)

Organisations (stubs — rounds 11–12)

  • Choosing Wisely — ABIM Foundation campaign (2012–2023); AAAAI items warn against indiscriminate IgE batteries and food IgE tests without a consistent history. (stub)
  • Evidence-Based Dermatology — Applying systematic reviews and trials to skin disease; Nottingham’s Centre of Evidence Based Dermatology founded Cochrane Skin. (stub)

Concepts (researched — round 3)

  • Steroid Phobia — Fear of topical steroids in about 20–80% of parents; roughly triples non-adherence and pushes families to ‘natural’ or unlabelled creams.

Concepts (researched — round 7)

  • Emollient Fire Risk — Dried emollient residue on fabric makes it ignite fast and burn hot; MHRA says this applies to paraffin-free products too.
  • Fingertip Unit — Cream along an adult fingertip (~0.5 g); age-banded FTU tables (e.g. 1–2 yrs face/neck 1.5 FTU) set toddler steroid doses.

Concepts (researched — round 9)

  • Cost of Eczema Care — What toddler eczema costs families and health systems: NHS unit prices, US out-of-pocket spend (median $860/yr), CAM and indirect costs.
  • Stepped Care Approach — NICE CG57 model: emollients always, add treatments by severity (mild/moderate/potent TCS, TCIs, bandages, phototherapy, systemics).
  • Treatment Outcomes Comparison — Track A (home/herbal) vs Track B (prescribed) for toddler eczema: effectiveness, speed, flare prevention, harms, cost, adherence, prognosis.

Concepts (stubs — round 4)

  • Kenji Sato — Japanese dermatologist (Hannan Chuo Hospital) credited with No Moisture Therapy and steroid-free atopic dermatitis care. (stub)

Concepts (stubs — round 12)

  • GRADE — Method Cochrane, NICE and WHO use to rate evidence certainty per outcome: high, moderate, low or very low. (stub)

General (researched — round 16)

  • Conclusion — Prescribed stepped care (emollient + right-strength steroid) beats home remedies; a few remedies are low-risk add-ons, several harm.

ClinicalTrials (researched — round 4)

  • LEAP Trial — RCT (NEJM 2015): early peanut eating in infants with severe eczema/egg allergy cut peanut allergy at 5 y from 13.7% to 1.9%.

ClinicalTrials (researched — rounds 11–12)

  • ALSPAC — UK Avon birth cohort (~14,700 children, 1990s); defined six eczema trajectories, most early eczema clears by 6–7 y; FLG drives persistence.
  • BATHE Trial — UK RCT (Santer, BMJ 2018) of 483 children aged 1–11: emollient bath additives added no benefit to standard eczema care.
  • BEE Trial — UK RCT (Ridd 2022) of 550 children 6 mo–12 y: lotions, creams, gels and ointments equally effective; ointments sting least.
  • BEEP Trial — UK RCT of 1,394 high-risk newborns: daily emollient in year 1 did not prevent eczema (age 2 or 5) and raised skin infections.
  • CLOTHES Trial — UK RCT (Thomas 2017, PLoS Med): silk garments added no benefit over standard care in 300 children aged 1–15
  • EAT Trial — UK RCT of early (3-month) introduction of six allergenic foods; ITT null, but per-protocol less peanut and egg allergy.
  • LIBERTY AD PRESCHOOL — Phase 3 RCT of dupilumab in 162 children aged 6 months–5 years with moderate-to-severe AD (Paller, Lancet 2022).
  • PEER Registry — US pimecrolimus safety registry (from 2004), 7,457 children aged 2–17; cancer rate no higher than expected (SIR 1.2); AD often persists.
  • SWET Trial — 2011 UK RCT of 336 children: ion-exchange water softeners gave no benefit over usual eczema care.
  • TREAT Trial — UK/Irish RCT (n=103, ages 2–16): ciclosporin vs methotrexate for severe childhood AD; CyA faster, MTX more durable.

ClinicalTrials (researched — round 15)

  • PreventADALL Trial — Norway/Sweden RCT (2,397 babies): early emollients did not prevent eczema or food allergy; early allergenic foods cut food allergy at 3.

ClinicalTrials (stubs — round 6)

  • PROBIT Trial — Belarusian cluster RCT (17,046 pairs): breastfeeding promotion halved first-year eczema (OR 0.54); flexural eczema lower at 16 years. (stub)

ClinicalTrials (stubs — rounds 8–9)

  • BAMSE — Swedish birth cohort of 4,089 Stockholm children (1994–96) tracking eczema, asthma and rhinitis into adolescence. (stub)
  • GADIS — German multicentre RCT (BMJ 2006, n=992): six weekly group education sessions improved SCORAD and parent quality of life. (stub)
  • Multicenter Allergy Study — German birth cohort (1,314 children born 1990) showing 43% of early eczema remits by age 3; severity predicts persistence. (stub)

ClinicalTrials (stubs — round 12)

  • PIAMA — Dutch birth cohort (n=3,652 analysed to age 11) that replicated ALSPAC’s six childhood eczema trajectories. (stub)

Conditions (researched — round 0)

  • Atopic Dermatitis — Chronic, itchy, relapsing inflammatory skin disease; peaks in infancy, shifts to flexures in toddlers; most but not all children improve

Conditions (researched — rounds 3–5)

  • Allergic Contact Dermatitis — Delayed (type IV) skin allergy to things touching the skin; ~1 in 3 patch-tested children with AD react; often missed as ‘just eczema’.
  • Atopic March — Classic AD → food allergy → asthma → hay fever sequence; Belgrave 2014 found under 7% of symptomatic children actually follow it.
  • Food Allergy — Food allergy is common alongside toddler eczema, but mostly a consequence or co-traveller of it, rarely the root cause.
  • Perioral Dermatitis — Rosacea-like papules around a child’s mouth, nose or eyes, often triggered by facial steroids; stop the steroid, use topical antibiotics.
  • Topical Steroid Withdrawal — Patient-named, poorly defined reaction after stopping prolonged potent steroids; regulators call it rare; only ~21 child cases published.

Conditions (researched — rounds 7–13)

  • Allergic Rhinitis — Hay fever: allergic nasal inflammation that often follows childhood eczema; ~44% of children with persistent infant eczema have it at 12.
  • Asthma — Chronic airway disease often co-occurring with childhood eczema; risk tracks eczema severity and persistence, not a fixed ‘march’.
  • Compositae Allergy — Contact allergy to daisy-family plants (chamomile, calendula, arnica); ~2–4% of patch-tested children; clusters in atopic kids; lifelong.
  • Differential Diagnosis of Toddler Eczema — Rashes that mimic toddler eczema (seborrhoeic, scabies, psoriasis, tinea, molluscum, nappy/contact) and red flags for immunodeficiency.
  • Drool Dermatitis — Irritant rash around the mouth and chin from saliva; common in teething babies and toddlers and can flare facial eczema
  • Eczema in Skin of Colour — On brown/black toddler skin eczema looks violaceous, grey or dark, often papular/follicular/extensor; redness-based scores under-rate it.
  • Eczema Prognosis — Whether toddlers outgrow eczema: many clear by school age, but severe, FLG-linked or sensitised disease persists more often.
  • Fragrance Allergy — Contact allergy to perfume chemicals; more common in children with AD; ‘unscented’ products and botanical extracts can contain fragrance.
  • HPA Axis Suppression — Absorbed steroid dampens cortisol; ~3.8% of children on TCS show reversible lab suppression. Clinically significant cases need misuse.
  • Ichthyosis Vulgaris — Inherited dry, fish-scale skin from filaggrin (FLG) loss; appears in infancy, often coexists with eczema, predicts earlier, persistent AD.
  • Impetigo — Contagious staph/strep infection with golden crusts; on eczema it is ‘impetiginised’. NICE first line, small patches: hydrogen peroxide 1%.
  • Irritant Contact Dermatitis — Non-allergic skin damage from repeated contact with irritants (saliva, urine, faeces, soaps); in toddlers mainly face, hands, nappy area.
  • Keratosis Pilaris — Harmless rough ‘chicken skin’ bumps on outer arms, thighs, cheeks; linked to atopic dermatitis and filaggrin; worse in winter.
  • Lichenification — Thickened, leathery skin with exaggerated criss-cross lines from chronic scratching; a marker of chronic, poorly controlled eczema.
  • Lip-Licker’s Dermatitis — Saliva irritant dermatitis from lip-licking: red scaly ring matching tongue reach, crosses lip border; worse in winter.
  • Molluscum Dermatitis — Eczema patches around molluscum spots; commoner and longer-lasting with AD; red inflamed spots (BOTE sign) usually mean clearing.
  • Nappy Rash — Nappy-area rash: mostly irritant (spares folds); candida = beefy folds + satellite spots; AD usually spares it. Barrier cream first.
  • Peanut Oil Sensitisation — Peanut (arachis) oil creams on inflamed infant skin linked to later peanut allergy (Lack 2003, OR 6.8); check UK labels for ‘arachis oil’.
  • Pityriasis Alba — Low-itch pale, finely scaly facial patches in children; a mild eczema linked to atopic dermatitis; clears over months to years.
  • Post-Inflammatory Hyperpigmentation — Darker patches left after eczema inflammation; most visible and longest-lasting on brown and black skin; fades over months.
  • Psoriasis — Sharply edged scaly plaques; in infants/toddlers often nappy area, scalp, behind ears; ~5% of children have AD–psoriasis overlap.
  • Scabies — Mite infestation; under-2s: palms, soles, face, scalp, armpit nodules; often mistaken for eczema; permethrin from 2 mo, whole household.
  • Seborrhoeic Dermatitis — Infant cradle cap/greasy fold rash; little itch, hits nappy and armpits (AD spares them); ~1 in 3 later develop AD.
  • Skin Atrophy — Steroid skin thinning; rare in children on guideline TCS (Hong 2011: 0/210 sites), mostly reversible; striae are permanent but rare.
  • Sleep Disturbance in Eczema — Over half of under-3s with eczema sleep poorly vs 30% of peers; parents lose sleep too. Fix is eczema control; sedatives only short-term.
  • Tree Nut Allergy — IgE allergy to tree nuts; ~3% of children by age 6, linked to eczema; almond and other nut oils on inflamed skin can sensitise.

Conditions (researched — round 15)

  • Conjunctivitis — Eye-surface inflammation; main specific dupilumab side effect in children (5% in preschool RCT, 19% over 2 years), mostly mild.
  • Eczema Trajectories — Six birth-cohort patterns of childhood eczema; most toddler eczema clears by school age; early-onset-persistent AD carries FLG/asthma risk.
  • Erythroderma — Red, inflamed skin over >90% of the body; a red flag in toddlers needing same-day/emergency care, often hospital; eczema is a leading cause.
  • Iatrogenic Cushing Syndrome — Steroid excess from absorbed medicine (moon face, high BP, poor growth); in toddlers nearly only after months of unsupervised strong TCS.

Conditions (stubs — rounds 0–1)

  • Folliculitis — Inflamed, bumpy hair follicles; a side effect of heavy ointment or prolonged occlusion such as overused wet wraps. (stub)
  • Netherton Syndrome — Rare genetic disorder (SPINK5/LEKTI loss) with uncontrolled skin proteases causing severe eczema-like disease (stub)

Conditions (stubs — round 4)

  • Essential Oil Poisoning — Swallowed eucalyptus, camphor, wintergreen or sage oils can cause vomiting, coma and seizures in toddlers within minutes to hours. (stub)
  • Kwashiorkor — Protein malnutrition; reported in toddlers on parent-led elimination diets (e.g. rice milk only) for eczema/presumed allergy. (stub)
  • Prepubertal Gynaecomastia — Breast growth in young boys (or early breasts in girls); 12 case reports linked to lavender/tea tree products; causation disputed. (stub)

Conditions (stubs — rounds 7–8)

  • Herpetic Gingivostomatitis — Typical first HSV-1 infection in 1–5-year-olds: fever, drooling, swollen bleeding gums and mouth ulcers. (stub)
  • Infant Botulism — Rare, serious gut infection in babies from Clostridium botulinum spores; why honey must not be eaten before 12 months. (stub)
  • Neonatal Herpes — Dangerous HSV infection in newborns; NHS warns that kissing a baby while having a cold sore can cause it. (stub)

Conditions (stubs — rounds 10–12)

  • Candidiasis — Yeast infection; in toddlers mainly nappy-area rash in the folds with satellite spots; treated with topical antifungal. (stub)
  • Cellulitis — Deeper bacterial skin infection (spreading redness, heat, pain, fever); a red flag in infected eczema needing oral antibiotics or hospital. (stub)
  • Hyper-IgE Syndrome — Rare immunodeficiencies (STAT3, DOCK8) with eczema, very high IgE and recurrent skin and chest infections. (stub)
  • Prurigo Nodularis — Very itchy firm nodules from chronic scratching; more common in eczema on darker skin. (stub)
  • Tinea — Fungal skin infection; annular patch with scaly active edge; may be mistaken for eczema and masked by steroids. (stub)
  • Wiskott-Aldrich Syndrome — X-linked immunodeficiency in boys: eczema indistinguishable from AD plus bleeding (small platelets) and recurrent infections. (stub)

Diagnostics (researched — round 5)

  • POEM — 7-question parent/patient-reported weekly eczema score (0–28); HOME core symptoms instrument; NICE-recommended; best home-tracking tool.

Diagnostics (researched — rounds 10–11)

  • EASI — Clinician-rated eczema severity score (0–72), HOME core signs tool; child multipliers 0–7 y; bands differ (Leshem 7/21 vs Chopra 6/23).
  • Hanifin-Rajka Criteria — 1980 AD diagnostic criteria: 3 of 4 major + 3 of 23 minor features; most used in trials but cumbersome in clinic and for toddlers.
  • Oral Food Challenge — Supervised graded feeding of a suspected food; the reference standard that sorts true allergy from the many false-positive tests in eczema.
  • Patch Testing — Gold-standard test for contact allergy; Pediatric Baseline Series (38 allergens) is for >6 y; toddlers need custom panels.
  • SCORAD — Clinician-led eczema severity index (0–103) mixing extent, 6 signs and parent-rated itch/sleep; bands ~<29 mild, 29–49 moderate, ≥49 severe.
  • Skin Prick Testing — Prick test for IgE sensitisation; in eczema up to half of children test positive but PPV is only 30–50%, so history must come first.
  • UK Working Party Criteria — Simplified AD criteria (itch + ≥3 of 5) usable without lab tests; NICE CG57 adapts them for under-4s; flexural item can miss extensor AD.

Diagnostics (researched — round 15)

  • Specific IgE Testing — Blood test for food/aeroallergen IgE; strong NPV but poor PPV in eczema, so only ordered for a matching reaction history.

Diagnostics (stubs — round 3)

  • TOPICOP Scale — 12-item validated questionnaire (worries + beliefs) scoring topical steroid fear 0–100% in patients and parents. (stub)

Diagnostics (stubs — round 11)

  • IgG Food Testing — Commercial IgG food panels; not a valid allergy or eczema test (AAAAI Choosing Wisely; NICE CG57 advises against high-street tests). (stub)
  • Repeat Open Application Test — Patch-test adjunct: apply the child’s own product to a small skin area repeatedly to mimic real use and confirm contact allergy. (stub)

Guidelines (researched — round 9)

  • South African Eczema Guidance — SA atopic dermatitis guidance (Sinclair et al SAMJ 2014/15; Kannenberg 2020 algorithm): cheap emollients, TCS/TCI, limited public access.
  • When to Refer — When toddler eczema needs referral: same-day (herpeticum), urgent (2 weeks), routine dermatology, allergy, growth and psychology criteria.

Guidelines (researched — rounds 12–13)

  • Fragrance-Free Labelling — ‘Fragrance-free’ means no added fragrance; ‘unscented’ can hide masking fragrance. The labels aren’t verified, so read the INCI list.
  • NICE NG153 — NICE 2020 impetigo guideline: hydrogen peroxide 1% first if localised; then fusidic acid, oral flucloxacillin/clarithromycin; 5 days.
  • NICE NG190 — NICE 2021: no routine antibiotics for infected eczema in a well child; fusidic acid or flucloxacillin 5–7 days if needed; check herpeticum.
  • Traditional Herbal Registration — UK MHRA herbal licence based on 30+ years’ traditional use: checks quality and safety, but needs no proof the product works.

Guidelines (researched — round 15)

  • AAD Pediatric Guideline 2026 — AAD’s first child-specific AD guideline (JAAD 2026): 27 GRADE recs; strong for emollients, TCS, TCIs, new non-steroids, dupilumab ≥6 mo.
  • NICE CG57 — NICE guideline ‘Atopic eczema in under 12s’ (2007, updated 2025): stepped care, emollients always, TCS potency by severity, referral rules.
  • Seal of Acceptance — NEA product mark (2008): no Ecz-clusion List ingredients or fragrance, adult patch tests, expert review; not proof it suits every child.

Guidelines (stubs — round 9)

  • EU Cosmetics Regulation — EU law requiring named fragrance allergens on cosmetic labels above 0.001% leave-on / 0.01% rinse-off; 56 added by 2023/1545. (stub)

Guidelines (stubs — round 13)

  • Pharmacy First — NHS England service letting pharmacists treat set conditions incl. localised impetigo (hydrogen peroxide 1%) from age 1, without a GP. (stub)

Mechanisms (researched — round 0)

  • Filaggrin — Skin structural protein whose gene (FLG) mutations are the strongest known genetic risk factor for early, persistent eczema
  • Skin Barrier Dysfunction — Leaky, dry outer skin layer (genes + environment) that lets irritants, allergens and S. aureus in, driving and sustaining toddler eczema
  • Th2 Immune Response — Type 2 inflammation (IL-4, IL-13, IL-31, IgE) that drives eczema itch and inflammation and erodes the skin barrier

Mechanisms (researched — rounds 2–6)

  • Ceramides — Barrier lipids depleted in eczema; ceramide creams sting less than urea, but paediatric RCTs show them no better than paraffin emollients.
  • Clothing and Fabrics — Wool and synthetics irritate eczema skin; cotton advised; silk gave no benefit (CLOTHES 2017); bio detergent enzymes not shown to harm.
  • Dual-Allergen Exposure Hypothesis — Lack’s theory: food protein via inflamed skin sensitises, early eating builds tolerance. Backed by LEAP; behind early-weaning guidance.
  • Environmental Triggers — Outside factors that irritate the barrier or provoke flares: soaps, heat, fabrics, mites, pets, pollen, climate, pollution, drool, illness.
  • House Dust Mites — Bedding mites whose droppings sensitise many eczema patients; Cochrane 2015 found no clear benefit from mite avoidance or mattress covers
  • Itch-Scratch Cycle — Self-reinforcing loop: itch → scratch → barrier damage and inflammation → more itch; drives toddler sleep loss, infection, lichenification.
  • Natural Moisturising Factor — Water-binding mix (amino acids, PCA, urocanic acid, lactate, urea, salts) from filaggrin breakdown; low in eczema, raising pH and dryness.
  • Pets and Eczema — Early-life dog ownership linked with less eczema; cat findings null or harmful with sensitisation or FLG mutation; rehoming is unproven.
  • Skin pH — Skin surface is acidic (pH 4–6); in eczema it rises, activating proteases, impairing ceramides, favouring Staph aureus. Soap raises it.
  • Transepidermal Water Loss — Water evaporating through the skin; a barrier-failure measure. High TEWL at day 2 and 2 months predicted eczema at 1 year (Kelleher 2015).

Mechanisms (researched — round 8)

  • Herpes Simplex Virus — Cold sore virus (mostly HSV-1), usually caught in early childhood by kissing; on eczema skin it can cause eczema herpeticum.

Mechanisms (researched — round 10)

  • Skin Microbiome — Skin microbe community; in flares diversity falls, S. aureus dominates (65% of untreated flares, Kong 2012); bacteriotherapy: trials only.
  • Sodium Lauryl Sulfate — Detergent in aqueous cream, toothpaste, shampoo, bubble bath; thinned the skin barrier 12% in 4 weeks (Tsang & Guy 2010); stings eczema.

Mechanisms (researched — rounds 12–13)

  • Antimicrobial Resistance — Fusidic acid/mupirocin-resistant S. aureus is enriched in eczema children and tracks prior topical use; why NICE limits antibiotic creams.
  • Gamma-Linolenic Acid — Omega-6 fatty acid in evening primrose, borage and blackcurrant seed oils; oral GLA supplements failed in 27 RCTs and lost their UK licence.
  • Heat and Sweat — Overheating, sweat and sudden temperature change provoke itch and flares; sweat can act as an allergen; rinse off sweat and keep cool.
  • Laundry Detergents — Washing powders/liquids; enzyme (bio) detergents did not worsen eczema in an RCT, but residue and perfumed fabric conditioner can irritate.
  • Linoleic Acid — Omega-6 fatty acid; plant oils with a high linoleic:oleic ratio (e.g. sunflower) are thought to support, not damage, the skin barrier.
  • MRSA — Meticillin-resistant Staph aureus; over-represented in eczema children; needs swab-guided antibiotics; recurrent carriage → decolonisation.
  • Oleic Acid — Omega-9 fatty acid dominant in olive oil; described as irritating and detrimental to the skin barrier (Vaughn 2018; Danby 2013).
  • Pollen — Tree/grass pollen can flare eczema on exposed skin in spring/summer; pollen sensitisation is uncommon under 2 but rises through toddlerhood.
  • Sesquiterpene Lactones — Reactive daisy-family compounds (chamomile, calendula, arnica) behind Compositae contact allergy, which is commoner in atopic children.

Mechanisms (researched — round 15)

  • Malassezia — Skin yeast behind cradle cap/seborrhoeic dermatitis and the main sweat allergen in AD; antifungals target it, not routine eczema care.
  • Roseomonas mucosa — Gram-negative skin commensal tested as topical ‘microbiome transplant’; promising open-label (2018), but FB-401 RCT (ages 2+) failed.

Mechanisms (stubs — rounds 2–4)

  • Avenanthramides — Oat-specific polyphenols with anti-inflammatory and anti-itch activity in lab and mouse models; proposed active in colloidal oatmeal. (stub)
  • Lauric Acid — Saturated fatty acid dominant in coconut oil; its monoglyceride monolaurin is antimicrobial against S. aureus in vitro. (stub)
  • Methylisothiazolinone — Preservative in wipes, washes, paints and slime; 3.7% of patch-tested Italian children positive; EU-restricted. (stub)

Mechanisms (stubs — round 6)

  • Air Pollution — Outdoor and indoor pollutants (PM2.5, NO2, VOCs, tobacco smoke) associated with eczema in observational studies (stub)
  • Aristolochic Acid — Kidney-toxic, carcinogenic plant compound; Aristolochia substituted into Chinese eczema remedies caused UK kidney failure cases. (stub)
  • Hygiene Hypothesis — Idea that early microbial exposure (e.g. from dogs, farms) trains the immune system away from allergy (stub)

Mechanisms (stubs — round 8)

  • Stearic Acid — Saturated C18 fatty acid; with oleic acid, a main component of shea butter; claimed to support the skin barrier. (stub)

Mechanisms (stubs — round 10)

Mechanisms (stubs — round 13)

  • Pyrrolizidine Alkaloids — Liver-toxic plant alkaloids found in borage, comfrey and others; a safety concern for oral borage oil supplements. (stub)

Remedies (researched — round 0)

Remedies (researched — rounds 2–4)

  • Calendula — Marigold extract in ‘natural’ baby balms; no atopic-dermatitis RCT; Compositae contact allergen (~2% of patch-tested patients).
  • Chamomile — Compositae herb in creams, baths, teas; one weak manufacturer trial; contact allergy, mugwort/ragweed cross-reaction and anaphylaxis risk.
  • Coconut Oil — Lauric-acid-rich oil; one paediatric RCT beat mineral oil and an adult trial cut S. aureus, but guidelines call its role undetermined.
  • Colloidal Oatmeal — FDA OTC skin protectant for eczema itch; paediatric RCT shows parity with barrier cream, but oat proteins can sensitise infants with AD.
  • Essential Oils — Distilled plant oils (tea tree, lavender); no AD efficacy data; contact allergens on broken skin and seizure-risk poisons if swallowed.
  • No Moisture Therapy — Online TSW regimen of stopping all moisturisers and limiting water/bathing; untested, against guidelines, risky for toddlers.
  • Olive Oil — Oleic-rich traditional skin oil that damaged the stratum corneum in adults and neonates; NICE says it is likely harmful to children’s skin.
  • Sunflower Seed Oil — Linoleic-rich oil that spared the adult barrier (Danby 2013) and cut preterm infections, but delayed neonatal lipid lamellae (Cooke 2016).

Remedies (researched — rounds 6–8)

  • Apple Cider Vinegar — Dilute ACV soaks lower skin pH for only ~15 min, don’t improve barrier or microbiome, and irritated 73% of users; burns reported.
  • Breast Milk — Topical breast milk: one infant RCT ≈ hydrocortisone 1%, toddler pilot found no effect. Breastfeeding’s prevention effect inconsistent.
  • Chinese Herbal Medicine — Oral/topical herbal formulas; early UK RCTs promising but Cochrane 2013 found no conclusive benefit; liver, kidney, hidden-steroid harms.
  • Evening Primrose Oil — Oral GLA-rich seed oil; Cochrane 2013 (27 RCTs) found it no better than placebo, and UK licences for Epogam were withdrawn in 2002.
  • Fish Oil and Omega-3 — Oral omega-3 (EPA/DHA) fish oil for eczema; small trials hint at benefit but Cochrane 2012 and AAD find no convincing evidence.
  • Lanolin — Sheep’s-wool emollient in nipple, nappy and baby balms; contact allergen, commoner in patch-tested children (4.5%) than adults (3.2%).
  • Manuka Honey — Topical honey: 5 tiny adult-heavy studies, the only RCT vs a control cream was negative. Never give honey by mouth under 12 months.
  • Prebiotics and Synbiotics — Gut-bacteria fibres (GOS/FOS), alone or with probiotics; weak eczema-prevention signal in formula-fed infants, not a treatment.
  • Probiotics — Oral live bacteria: no real benefit for treating eczema (Cochrane 2018); weak, contested evidence for prevention via maternal/perinatal use.
  • Shea Butter — West African nut fat in many eczema creams; two small paediatric product studies only; refined shea has no detectable nut protein.
  • Vitamin D — Oral vitamin D: children with eczema tend to have lower levels; some RCTs (Camargo 2014) and meta-analyses show modest benefit, others none.

Remedies (researched — round 13)

  • Almond Oil — Nut oil common in baby massage oils and ‘natural’ balms; no eczema trials, and it sensitised an AD infant to almond through the skin.
  • Borage Oil — Oral GLA seed-oil supplement; Cochrane 2013 (8 RCTs) found no benefit over placebo, and borage carries a liver-toxic alkaloid concern.

Remedies (stubs — rounds 9–11)

  • Arachis Oil — Label name for peanut oil in UK/EU medicines and cosmetics; contraindicated in peanut or soya allergy under EMA excipient rules. (stub)
  • Argan Oil — Cold-pressed tree-nut oil in cosmetics; anaphylaxis reported after skin application (JIACI 2021). (stub)
  • Arnica — Daisy-family herbal bruise remedy; a Compositae contact allergen tested by plant extract in patch testing. (stub)
  • Homeopathy — Highly diluted remedies sometimes recommended on parent forums for eczema; no reliable evidence of benefit beyond placebo. (stub)

Remedies (stubs — round 13)

  • Feverfew — Daisy-family herb whose sesquiterpene lactone parthenolide is a standard patch-test allergen for Compositae allergy. (stub)

Treatments (researched — round 0)

  • Aqueous Cream — SLS-containing cream no longer advised as a leave-on emollient for eczema; stung in 56% of child exposures in one clinic audit.
  • Emollient Therapy — Daily unperfumed moisturisers are first-line for toddler eczema; lotion, cream, gel and ointment work equally; they treat, not prevent.
  • Topical Corticosteroids — First-line anti-inflammatory creams for eczema flares; mild potency for toddler face/folds, once daily works, weekend use prevents flares.

Treatments (researched — rounds 2–5)

  • Crisaborole — Steroid-free PDE4-inhibitor ointment (Eucrisa); US-licensed from 3 months since 2020; EU licence withdrawn 2022; stings in some.
  • Dupilumab — IL-4Rα antibody injection licensed from 6 months (US mod-severe, EU severe only); strong preschool RCT; conjunctivitis main side effect.
  • Elimination Diets — Cutting foods to treat eczema: at best a slight benefit (Oykhman 2022), with real risks of new IgE allergy and malnutrition.
  • JAK Inhibitors — JAK-blocking AD drugs: oral abrocitinib/upadacitinib ≥12 y, EU baricitinib ≥2 y; US ruxolitinib cream ≥2 y (2025); boxed warnings.
  • Soak and Seal — Lukewarm soak, pat damp, then medicine on patches and emollient everywhere within ~3 min; twice-daily soaks cut SCORAD 21 points (2020 RCT).
  • Systemic Immunosuppressants — Oral ciclosporin/methotrexate for severe childhood AD; TREAT RCT (2–16 y): ciclosporin faster, methotrexate more durable; both off-label.
  • Topical Calcineurin Inhibitors — Steroid-free tacrolimus/pimecrolimus; no skin thinning, suits face/eyelids; US cancer boxed warning vs reassuring 3.4M-patient data.
  • Urea Creams — Urea humectant emollients (2–10% for eczema): low-quality evidence of benefit, more side effects than control; often sting raw toddler skin.
  • Weekend Therapy — Proactive twice-weekly TCS (or TCI) on usual flare sites after control; cuts flares (NNT≈3) with no thinning seen in trials.

Treatments (researched — rounds 7–13)

  • Aciclovir — Antiviral for herpes simplex; immediate oral or IV aciclovir is standard for suspected eczema herpeticum. Each day of delay lengthens stay.
  • Clarithromycin — Oral macrolide; NICE’s alternative to flucloxacillin for infected eczema or impetigo if penicillin-allergic or fluclox liquid is refused.
  • Clobetasol Propionate — Very potent (UK) / group I (US) topical steroid; specialist-only in children; the hidden steroid most often found in fake ‘herbal’ creams.
  • Clobetasone Butyrate — Moderate-potency TCS (Eumovate 0.05%); a step up from hydrocortisone. UK OTC pack is 12+ only, so toddlers need a prescription.
  • Eczema Care Online — Free UK online self-care programme for parents; Santer 2022 BMJ RCT showed a small, lasting POEM improvement (−1.5) in children 0–12.
  • Eczema Education Programmes — Structured parent education (eczema schools, nurse clinics); GADIS RCT improved SCORAD and parent QoL; Cochrane calls evidence limited.
  • Emollient Bath Additives — Oils/emulsions poured into bath water; BATHE RCT found no added benefit in children 1–11, so NHS England and NICE no longer advise them.
  • Erythromycin — Macrolide for toddler perioral dermatitis; NICE uses it for impetigo/infected eczema only in pregnancy, clarithromycin otherwise.
  • Flucloxacillin — Anti-staph penicillin; NICE first-choice oral antibiotic for infected eczema/impetigo; bitter liquid; clarithromycin if allergic.
  • Fucidin H — 2% fusidic acid + 1% hydrocortisone cream for infected eczema; leaflet allows up to 2 weeks, beyond NICE’s 5–7 days for fusidic acid.
  • Fusidic Acid — Topical anti-staph antibiotic; NICE limits it to 5–7 day courses for localised infection because overuse in eczema drives resistance.
  • Glycerol — Humectant in many standard emollients; RCTs show it improves skin hydration and modestly helps eczema, with less stinging than urea.
  • Hydrocortisone — Mild-potency TCS (0.5/1/2.5%); default for toddler face, neck and nappy area. UK OTC only for 10+, US OTC (≤1%) for 2+.
  • Hydrogen Peroxide Cream — Crystacide 1% antiseptic cream; NICE NG153 first-line for localised non-bullous impetigo, sparing topical antibiotics; no known resistance.
  • Mineral Oil — Refined petroleum oil (liquid paraffin) in licensed emollients; beaten by virgin coconut oil in one child RCT; fire risk on fabric.
  • Mupirocin — Topical antibiotic (Bactroban); NICE switch if fusidic acid resistance suspected; nasal decolonisation; resistance follows repeated use.
  • Oral Antihistamines — Cochrane 2019: no convincing evidence oral H1 antihistamines help eczema; NICE allows short trials; sedating types risky in toddlers.
  • Petrolatum — Most occlusive emollient base; penetrates stratum corneum, speeds barrier repair; rarely allergenic; no benefit for infant prevention.
  • Phototherapy — Hospital narrowband UVB for severe eczema; child data start at age 4; rarely used in toddlers (practicalities, lifetime cancer concern).
  • Pimecrolimus — Calcineurin-inhibitor cream (Elidel 1%) for mild-moderate eczema; UK licence from 3 months, US/SA from 2 years.
  • Ruxolitinib Cream — Topical JAK1/2 inhibitor (Opzelura); US from age 2 (Sept 2025) after TRuE-AD3; boxed warning; ≤20% BSA, 60 g/2 wk; EU adults only.
  • Soap Substitutes — Washing with a leave-on emollient or soap-free wash instead of alkaline soap; clinical consensus, untested in trials, cheap and safe.
  • Syndet Cleansers — Synthetic-detergent cleansers (pH 5.5–7) that strip less lipid and shift skin pH less than soap; liquids more reliably acidic than bars.
  • Tacrolimus — Calcineurin-inhibitor ointment (Protopic 0.03%/0.1%); 0.03% licensed from age 2; steroid-free option for face/eyelids.
  • Written Eczema Action Plan — Personalised one-page plan: daily emollient, which steroid where in flares, step-down, when to get help. Guideline-backed; trials thin.

Treatments (researched — round 15)

  • Bacteriotherapy — Experimental treatment applying live protective skin bacteria (S. hominis A9, R. mucosa); the one placebo RCT including 2-year-olds failed.
  • Barrier Creams — Protective ointments (petrolatum, zinc oxide, dimeticone) applied thinly to nappy and drool areas to shield skin from urine, faeces, saliva.
  • Decolonisation — Clearing carried staph from nose and skin (nasal mupirocin/fusidic acid, antiseptic washes) after swabs, only for frequent recurrences.
  • Habit Reversal — Behavioural technique swapping habitual scratching for a competing action (fist clench, pressing); small RCTs show benefit added to TCS.
  • Permethrin — First-line scabies cream; UK/FDA licensed from 2 months, under-2s only under medical supervision; 1–5s up to ¼ tube; treat whole household.
  • Roflumilast Cream — Once-daily steroid-free PDE4 cream (Zoryve); US-licensed 0.05% for ages 2–5 since Oct 2025; not licensed in EU or UK.
  • Tapinarof Cream — Once-daily steroid-free AhR-agonist cream (Vtama); US-licensed for AD from age 2 since Dec 2024; folliculitis common; not licensed in EU/UK.
  • Tetracyclines — Oral antibiotics, first-line for adult perioral dermatitis; avoided in young children (tooth staining), though short doxycycline looks safe.

Treatments (stubs — round 4)

  • Metronidazole — Topical antibiotic/anti-inflammatory gel widely used first-line for periorificial dermatitis in children. (stub)
  • Neomycin — Over-the-counter topical antibiotic; a top paediatric contact allergen for decades; patch reactions can appear late. (stub)

Treatments (stubs — round 7)

  • Chlorphenamine — Sedating first-generation antihistamine (Piriton); used short-term for eczema sleep loss; paradoxical excitation risk in young children. (stub)

Treatments (stubs — round 13)

  • Clindamycin — Lincosamide antibiotic; oral option for minor MRSA skin infection and a topical option for perioral dermatitis in children. (stub)

UserFeedback (researched — round 10)

  • Parent Experiences — What parents of 1–4 year olds say worked, failed and wore them down — forum anecdotes set against peer-reviewed qualitative studies.

UserFeedback (researched — round 15)

  • Online Parenting Forums — Reddit, Mumsnet, Facebook groups where parents swap eczema advice; valued for support but can amplify steroid fears and untested changes.

Open Questions

Graph View